Domain Therapeutics, a Strasbourg, France-based biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs), has completed a €2m financing.
Half of the funds have been provided by new investor Seventure Partners and the other half has been committed by new investor SODIV and existing shareholders AIRFI, IP Growth, Auriga and Sam Eletr, the chairman of the company’s board.
Led by CEO Pascal Neuville, Domain Therapeutics discovers allosteric modulators by exploiting its proprietary DTect-All (TM) technology. Its pipeline is composed of new chemical entities, ranging from hits to optimized leads for significant indications such as schizophrenia, Parkinson’s disease and diabetes. Some 30 high-throughput screening assays targeting high-potential GPCRs will soon be added to the company’s existing portfolio.
Domain Therapeutics intends to use the funds to transit from contract research activities for the pharmaceutical industry to collaborations and strategic alliances with existing clients and new partners for discovering drugs targeting GPCRs.